News | Heart Failure | May 18, 2018

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Subgroup analysis of FIX-HF-5 study found CCM therapy with Optimizer device significantly improved exercise tolerance and quality of life for one subset of heart failure patients

Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

May 18, 2018 — In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise tolerance (ET) and quality of life (QoL) for patients with persistent symptomatic heart failure and an ejection fraction between 25 and 45 percent.  Results of the prospective FIX-HF-5C Study were presented at the 2018 Heart Rhythm Society (HRS) Scientific Sessions, May 9-12 in Boston.                     

CCM therapy for patients with persistent symptomatic heart failure (NYHA Class III and IV) consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. The objective of the prospective FIX-HF-5C study was to confirm a subgroup analysis of a prior study (FIX- HF-5) showing that CCM significantly improved ET and QoL in the target patient group.

One hundred and sixty patients were randomized to continued medical therapy alone (Control) or to continued medical therapy plus CCM delivered by Impulse Dynamics’ Optimizer system (Treatment) for 24 weeks. All patients had NYHA III or IV symptoms despite guideline recommended therapy, QRS duration <130ms and LVEF 25-45 percent. Peak VO2 (pVO2, primary endpoint), Minnesota Living with Heart Failure Questionnaire (MLWHFQ), NYHA and six-minute hall walk (6MHW) test were measured at baseline, 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis, with 30 percent borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events, with a prespecified lower bound of 70 percent.

The difference in pVO2 between Treatment and Control was 0.836 mlO2/kg/min with a 95 percent Bayesian credible interval of (0.123, 1.552 mlO2/kg/min), satisfying the primary endpoint. MLWHFQ (p<0.001), NYHA (p<0.001) and 6MHW (p=0.01) were all better in Treatment vs Control. There were seven device-related events, yielding a lower bound of 80% of patients free of events.

For more information: www.hrssessions.org

Related HRS Content

Heart Rhythm 2018 Late-breaking Studies

Long-Term Data Demonstrate Safety, Efficacy of Optimizer System

Related Content

BIO-AffectDX is a multi-center, observational study that will enroll HF patients with paroxysmal, persistent and long-standing persistent AF, and a standard CRT-D indication. The study will include up to 400 participants implanted with a Biotronik Acticor CRT-DX system.

BIO-AffectDX is a multi-center, observational study that will enroll HF patients with paroxysmal, persistent and long-standing persistent AF, and a standard CRT-D indication. The study will include up to 400 participants implanted with a Biotronik Acticor CRT-DX system.

News | Cardiac Resynchronization Therapy Devices (CRT) | August 03, 2021
August 3, 2021 — In association with Heart Rhythm 2021, Biotro
News | Cardiac Resynchronization Therapy Devices (CRT) | March 03, 2021
March 3, 2021 — Medtronic announced new results from the landmark...
Left bundle branch (LBBP) activation imaging shown using wall motion color codes on echo imaging from Canon. #HRS2020 #heartrhythm2020

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on dyamic echo imaging from Canon. 

News | Cardiac Resynchronization Therapy Devices (CRT) | May 13, 2020
May 13, 2020 —...
Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Feature | Cardiac Resynchronization Therapy Devices (CRT) | March 09, 2020 | Valentina Kutyifa M.D., Ph.D.
Cardiovascular disease is the leading cause of death for women in North America, and women with...
His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...